WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Pfizer awards more than $1 million in metastatic breast cancer research funding 13 May 2016
Pfizer reports first-quarter 2016 results 03 May 2016
Pfizer announces termination of proposed combination with Allergan 07 April 2016
Bristol-Myers Squibb and Pfizer announce global real-world data program and present new analyses of Eliquis (apixaban) 30 March 2016
Pfizer celebrates a year of achievements in 2015 annual review 16 March 2016
Pfizer commences $5 billion accelerated share repurchase 11 March 2016
Merck, Pfizer and Verastem announce combination trial of avelumab and VS-6063 in ovarian cancer 04 March 2016
Pfizer names executive leadership team for combined organization upon close of proposed Allergan transaction 08 February 2016
Bristol-Myers Squibb and Pfizer sign collaboration with Portola Pharmaceuticals 02 February 2016
Pfizer expands R&D equity investment strategy to access early-stage scientific innovations 13 January 2016
Merck KGaA, Darmstadt, Germany, Pfizer and Syndax announce collaboration to evaluate combination of Avelumab and Entinostat in ovarian cancer 04 January 2016
Global partners announce donation of 500 millionth dose of azithromycin 17 November 2015
Pfizer expands its patient assistance program 10 November 2015
Pfizer completes acquisition of Nimenrix and Mencevax from GlaxoSmithKline 06 October 2015
New Centrum® VitaMints® offer a refreshingly new way to take a multivitamin 24 September 2015
Pfizer and Synthon enter into U.S. commercialization agreement for potential generic treatment of multiple sclerosis 04 August 2015
Pfizer's Centers for Therapeutic Innovation and Jeffrey Modell Foundation announce collaboration 13 July 2015
Pfizer enters into agreement to acquire Nimenrix and Mencevax from GlaxoSmithKline 23 June 2015
Get Ready. Get Set. Get Old. 04 June 2015
Pfizer announces $3 million grants program to further clinical research in advanced breast cancer 28 May 2015
  • Start
  • Prev
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • Next
  • End

Business & Industry

  • GSK completes acquisition of Sierra Oncology
  • Pfizer and BioNTech announce new agreement with U.S. government to provide additional doses of COVID-19 vaccine
  • Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
  • New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
  • Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron

Research & Development

  • Inhalable COVID-19 vaccine shows promise in rodent model
  • Researchers discover new leukemia-killing compounds
  • Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by researchers
  • Biomarkers found that could be drug targets against a deadly form of brain cancer
  • COVID-19 rebound after taking Paxlovid likely due to insufficient drug exposure
  • Novel drug combo activates natural killer cell immunity to destroy cancer cells
  • Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants

Conferences & Events

  • New approach to treatment of deadly kidney cancer
  • SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
  • Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
  • SMi's 22nd Annual Pain Therapeutics Conference
  • SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
  • SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
  • SMi's 3rd Annual AI in Drug Discovery Conference

Regulatory Affairs

  • FDA approves first systemic treatment for alopecia areata
  • FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
  • FDA limits use of Janssen COVID-19 vaccine to certain individuals
  • EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
  • FDA approves first generic of Symbicort to treat asthma and COPD
  1. You are here:  
  2. Home
  3. Pfizer
  4. Pfizer and BioNTech announce new agreement with U.S. government to provide additional doses of COVID-19 vaccine

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2022. All Rights Reserved.